Kayla Britt 5/25/26 Kayla Britt 5/25/26

Bounding the Uncertainty: An Error Taxonomy for Non-Deterministic AI in Regulated Life Sciences

Kayla Britt 5/6/26 Kayla Britt 5/6/26

When Your AI Vendor Passes SOC 2 — and Still Fails GxP

Kayla Britt 4/23/26 Kayla Britt 4/23/26

The Safety Paradox: Why Frozen Models Aren’t Always Safer Than Agentic Ones

Kayla Britt 4/3/26 Kayla Britt 4/3/26

The $100M Question Your AI Can't Answer (Yet): Why Validation Is the Missing Variable in Pharma's AI ROI

Kayla Britt 3/25/26 Kayla Britt 3/25/26

Your Frozen Architecture May Have a Backdoor

Kayla Britt 3/14/26 Kayla Britt 3/14/26

Why AI Governance Fails Without a Control Layer: A House-of-Trust Model for Regulated Drug Development

Kayla Britt 2/23/26 Kayla Britt 2/23/26

The Guidance Says What. The Next 12 Articles Show How

Kayla Britt 2/11/26 Kayla Britt 2/11/26

AI Trust is not a feeling - It’s a Validation Strategy

Kayla Britt 2/4/26 Kayla Britt 2/4/26

The Engineering of Uncertainty: Transparency in the Probabilistic Era

Kayla Britt 1/22/26 Kayla Britt 1/22/26

Human-in-the-Loop, Liability Still in Play

Kayla Britt 1/14/26 Kayla Britt 1/14/26

FDA & EMA Just Released AI Guiding Principles for Drug Development: Here’s What They Actually Mean

Kayla Britt 1/6/26 Kayla Britt 1/6/26

History Rhymes: Why AI is the "Paper-to-Digital" Shift of Our Generation

Kayla Britt 12/16/25 Kayla Britt 12/16/25

The Capability Paradox: Why Soaring LLM Benchmarks Demand Stricter Validation

Kayla Britt 12/8/25 Kayla Britt 12/8/25

FDA’s Agentic AI Announcement Signals a New Era for Scientific Computing

Kayla Britt 11/17/25 Kayla Britt 11/17/25

Data drift: a risk-based and gamp-aligned approach

Kayla Britt 11/7/25 Kayla Britt 11/7/25

From Pilot to Production: A Practical Roadmap for LLM Implementation in GxP Environments

Bounding the Uncertainty: An Error Taxonomy for Non-Deterministic AI in Regulated Life Sciences

When Your AI Vendor Passes SOC 2 — and Still Fails GxP

The Safety Paradox: Why Frozen Models Aren’t Always Safer Than Agentic Ones

The $100M Question Your AI Can't Answer (Yet): Why Validation Is the Missing Variable in Pharma's AI ROI

Your Frozen Architecture May Have a Backdoor

Why AI Governance Fails Without a Control Layer: A House-of-Trust Model for Regulated Drug Development

The Guidance Says What. The Next 12 Articles Show How

AI Trust is not a feeling - It’s a Validation Strategy

The Engineering of Uncertainty: Transparency in the Probabilistic Era

Human-in-the-Loop, Liability Still in Play

FDA & EMA Just Released AI Guiding Principles for Drug Development: Here’s What They Actually Mean

History Rhymes: Why AI is the "Paper-to-Digital" Shift of Our Generation

The Capability Paradox: Why Soaring LLM Benchmarks Demand Stricter Validation

FDA’s Agentic AI Announcement Signals a New Era for Scientific Computing

Data drift: a risk-based and gamp-aligned approach

From Pilot to Production: A Practical Roadmap for LLM Implementation in GxP Environments

Fit-For-Purpose LLMs: Why it Matters

Validation for LLMs: An interdisciplinary perspective